225 related articles for article (PubMed ID: 34655242)
61. Phospholipid abnormalities in children with Barth syndrome.
Schlame M; Kelley RI; Feigenbaum A; Towbin JA; Heerdt PM; Schieble T; Wanders RJ; DiMauro S; Blanck TJ
J Am Coll Cardiol; 2003 Dec; 42(11):1994-9. PubMed ID: 14662265
[TBL] [Abstract][Full Text] [Related]
62. Barth syndrome in a female patient.
Cosson L; Toutain A; Simard G; Kulik W; Matyas G; Guichet A; Blasco H; Maakaroun-Vermesse Z; Vaillant MC; Le Caignec C; Chantepie A; Labarthe F
Mol Genet Metab; 2012 May; 106(1):115-20. PubMed ID: 22410210
[TBL] [Abstract][Full Text] [Related]
63. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide.
Sabbah HN
Heart Fail Rev; 2021 Mar; 26(2):237-253. PubMed ID: 33001359
[TBL] [Abstract][Full Text] [Related]
64. Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome.
Angelini R; Russo S; Corcelli A; Lobasso S
J Vis Exp; 2022 Mar; (181):. PubMed ID: 35404345
[TBL] [Abstract][Full Text] [Related]
65. Identification of novel mitochondrial localization signals in human Tafazzin, the cause of the inherited cardiomyopathic disorder Barth syndrome.
Dinca AA; Chien WM; Chin MT
J Mol Cell Cardiol; 2018 Jan; 114():83-92. PubMed ID: 29129703
[TBL] [Abstract][Full Text] [Related]
66. Characterization of lymphoblast mitochondria from patients with Barth syndrome.
Xu Y; Sutachan JJ; Plesken H; Kelley RI; Schlame M
Lab Invest; 2005 Jun; 85(6):823-30. PubMed ID: 15806137
[TBL] [Abstract][Full Text] [Related]
67. Cardiolipin remodeling in Barth syndrome and other hereditary cardiomyopathies.
Bertero E; Kutschka I; Maack C; Dudek J
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165803. PubMed ID: 32348916
[TBL] [Abstract][Full Text] [Related]
68. Loss of Mitochondrial Ca
Bertero E; Nickel A; Kohlhaas M; Hohl M; Sequeira V; Brune C; Schwemmlein J; Abeßer M; Schuh K; Kutschka I; Carlein C; Münker K; Atighetchi S; Müller A; Kazakov A; Kappl R; von der Malsburg K; van der Laan M; Schiuma AF; Böhm M; Laufs U; Hoth M; Rehling P; Kuhn M; Dudek J; von der Malsburg A; Prates Roma L; Maack C
Circulation; 2021 Nov; 144(21):1694-1713. PubMed ID: 34648376
[TBL] [Abstract][Full Text] [Related]
69. Current and future treatment approaches for Barth syndrome.
Thompson R; Jefferies J; Wang S; Pu WT; Takemoto C; Hornby B; Heyman A; Chin MT; Vernon HJ
J Inherit Metab Dis; 2022 Jan; 45(1):17-28. PubMed ID: 34713454
[TBL] [Abstract][Full Text] [Related]
70. Unremodeled and remodeled cardiolipin are functionally indistinguishable in yeast.
Baile MG; Sathappa M; Lu YW; Pryce E; Whited K; McCaffery JM; Han X; Alder NN; Claypool SM
J Biol Chem; 2014 Jan; 289(3):1768-78. PubMed ID: 24285538
[TBL] [Abstract][Full Text] [Related]
71. Dysfunctional cardiac mitochondrial bioenergetic, lipidomic, and signaling in a murine model of Barth syndrome.
Kiebish MA; Yang K; Liu X; Mancuso DJ; Guan S; Zhao Z; Sims HF; Cerqua R; Cade WT; Han X; Gross RW
J Lipid Res; 2013 May; 54(5):1312-25. PubMed ID: 23410936
[TBL] [Abstract][Full Text] [Related]
72. Single Cell Transcriptomic Analysis in a Mouse Model of Barth Syndrome Reveals Cell-Specific Alterations in Gene Expression and Intercellular Communication.
Perera G; Power L; Larson A; Codden CJ; Awata J; Batorsky R; Strathdee D; Chin MT
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511352
[TBL] [Abstract][Full Text] [Related]
73. Cardiolipin deficiency elevates susceptibility to a lipotoxic hypertrophic cardiomyopathy.
Cole LK; Mejia EM; Sparagna GC; Vandel M; Xiang B; Han X; Dedousis N; Kaufman BA; Dolinsky VW; Hatch GM
J Mol Cell Cardiol; 2020 Jul; 144():24-34. PubMed ID: 32418915
[TBL] [Abstract][Full Text] [Related]
74. Anomalous peroxidase activity of cytochrome c is the primary pathogenic target in Barth syndrome.
Kagan VE; Tyurina YY; Mikulska-Ruminska K; Damschroder D; Vieira Neto E; Lasorsa A; Kapralov AA; Tyurin VA; Amoscato AA; Samovich SN; Souryavong AB; Dar HH; Ramim A; Liang Z; Lazcano P; Ji J; Schmidtke MW; Kiselyov K; Korkmaz A; Vladimirov GK; Artyukhova MA; Rampratap P; Cole LK; Niyatie A; Baker EK; Peterson J; Hatch GM; Atkinson J; Vockley J; Kühn B; Wessells R; van der Wel PCA; Bahar I; Bayir H; Greenberg ML
Nat Metab; 2023 Dec; 5(12):2184-2205. PubMed ID: 37996701
[TBL] [Abstract][Full Text] [Related]
75. The functions of cardiolipin in cellular metabolism-potential modifiers of the Barth syndrome phenotype.
Raja V; Greenberg ML
Chem Phys Lipids; 2014 Apr; 179():49-56. PubMed ID: 24445246
[TBL] [Abstract][Full Text] [Related]
76. The cardiolipin transacylase, tafazzin, associates with two distinct respiratory components providing insight into Barth syndrome.
Claypool SM; Boontheung P; McCaffery JM; Loo JA; Koehler CM
Mol Biol Cell; 2008 Dec; 19(12):5143-55. PubMed ID: 18799610
[TBL] [Abstract][Full Text] [Related]
77. A critical appraisal of the tafazzin knockdown mouse model of Barth syndrome: what have we learned about pathogenesis and potential treatments?
Ren M; Miller PC; Schlame M; Phoon CKL
Am J Physiol Heart Circ Physiol; 2019 Dec; 317(6):H1183-H1193. PubMed ID: 31603701
[TBL] [Abstract][Full Text] [Related]
78. Cardiolipin metabolism regulates expression of muscle transcription factor MyoD1 and muscle development.
Vo L; Schmidtke MW; Da Rosa-Junior NT; Ren M; Schlame M; Greenberg ML
J Biol Chem; 2023 Mar; 299(3):102978. PubMed ID: 36739949
[TBL] [Abstract][Full Text] [Related]
79. Cardiolipin metabolism and the role it plays in heart failure and mitochondrial supercomplex formation.
Mejia EM; Cole LK; Hatch GM
Cardiovasc Hematol Disord Drug Targets; 2014; 14(2):98-106. PubMed ID: 24801725
[TBL] [Abstract][Full Text] [Related]
80. AAV-Mediated TAZ Gene Replacement Restores Mitochondrial and Cardioskeletal Function in Barth Syndrome.
Suzuki-Hatano S; Saha M; Rizzo SA; Witko RL; Gosiker BJ; Ramanathan M; Soustek MS; Jones MD; Kang PB; Byrne BJ; Cade WT; Pacak CA
Hum Gene Ther; 2019 Feb; 30(2):139-154. PubMed ID: 30070157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
